|
BP14295
|
Y06137
|
|
|
|
|
Y06137 is an effective and selective BET inhibitor with a Kd of 81 nM for BRD4(1) bromodomain. Y06137 can be used for research on the treatment of castration-resistant prostate cancer.
|
|
BP14294
|
Y06036
|
|
|
|
|
Y06036, a potent and selective BET inhibitor, can bind to the BRD4(1) bromodomain (Kd: 82 nM).
|
|
BP14293
|
XY1
|
|
|
|
|
XY1 is a very close analogue of SGC707 (a potent, selective, and non-competitive inhibitor of PRMT3 with IC50 of 31 nM), It is intended to be used as a negative control for SGC707 in studies involving PRMT3 action.
|
|
BP14292
|
XMD-17-51 Trifluoroacetate
|
|
|
|
|
XMD-17-51 Trifluoroacetate is a potent and highly selective NUAK1 inhibitor.
|
|
BP14291
|
XMD-17-51
|
|
|
|
|
XMD-17-51 is a potent and highly selective NUAK1 inhibitor.
|
|
BP14290
|
XD14
|
|
|
|
|
XD14 is an inhibitor of BET bromodomain (Kd of 160 nM, 170 nM, 380 nM, 490 nM, 830 nM and 850 nM for BRD4(1), BRD2(1), BRD3(1), BRD3(2), BRD2(2) and BRD4(2), respectively).
|
|
BP14289
|
XAV-939
|
|
|
|
|
XAV-939 shows the selective inhibition against Wnt/β-catenin-mediated transcription by tankyrase1/2 inhibition (IC50: 11/4 nM in cell-free assays).
|
|
BP14288
|
WZ4003
|
|
|
|
|
WZ4003, a highly selective NUAK kinase inhibitor, is with IC50 of 20 nM and 100 nM for NUAK1 and NUAK2, respectively. It is no significant inhibition on 139 other kinases.
|
|
BP14287
|
WP1066
|
|
|
|
|
WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3. WP1066 has been used in trials studying the treatment of Melanoma, Brain Cancer, Solid Tumors, and Central Nervous System Neoplasms.
|
|
BP14286
|
WM-1119
|
|
|
|
|
WM-1119 is a highly potent, selective KAT6A/B inhibitor
|
|
BP14285
|
WIKI4
|
|
|
|
|
WIKI4 is a potent inhibitor of Wnt/β-catenin signaling and tankyrase 2 (TNKS2).
|
|
BP14284
|
WHI-P97
|
|
|
|
|
WHI-P97 is a rationally designed potent inhibitor of JAK-3. IC50 value: Target: JAK3 Treatment of mast cells with WHI-P97 inhibited the translocation of 5-lipoxygenase (5-LO) from the nucleoplasm to the nuclear membrane and consequently 5-LO-dependent leukotriene (LT) synthesis after IgE receptor/FcepsilonRI crosslinking by >90% at low micromolar concentrations. WHI-P97 did not directly inhibit the enzymatic activity of 5-LO, but prevented its translocation to the nuclear membrane without affecting the requisite calcium signal.
|
|
BP14283
|
WH-4-025
|
|
|
|
|
WH-4-025 is a Salt-inducible kinase (SIK) inhibitor.
|
|
BP14282
|
WAY-309060
|
|
|
|
|
WAY-309060 is a BRD4 small molecule inhibitor with antitumor activity.
|
|
BP14281
|
VZ185
|
|
|
|
|
VZ185 is an effective and selective dual BRD7/9 PROTAC degrader (DC50s: 4.5 and 1.8 nM, respectively).
|
|
BP14280
|
VTX-27
|
|
|
|
|
VTX-27 is a selective inhibitor of protein kinase C θ (PKC θ) (Kis: 0.08 nM and 16 nM for PKC θ and PKC δ).
|
|
BP14279
|
Venadaparib
|
|
|
|
|
Venadaparib (IDX-1197) is a potent, selective and orally active PARP inhibitor with IC50s of 1.4 nM and 1.0 nM for PARP1 and PARP2, respectively. Venadaparib is insensitive to PARP-5. Venadaparib prevents the repair of DNA single-strand breaks (SSBs) and can be used in solid tumor research.
|
|
BP14278
|
EHP-101
|
|
|
|
|
VCE-004.8 is a specific dual agonist of PPARγ and CB2 receptor with potent anti-inflammatory activity. VCE-004.8 attenuates adipogenesis and prevents diet-induced obesity.
|
|
BP14277
|
Valrubicin
|
|
|
|
|
Valrubicin (AD 32) inhibits TPA- and PDBu-induced PKC activation (IC50s: 0.85 and 1.25 μM) and has antitumor and anti-inflammatory activity.
|
|
BP14276
|
Valemetostat tosylate
|
|
|
|
|
Valemetostat tosylate is a dual inhibitor of EZH1/2 and used in the research of relapsed/refractory peripheral T-cell lymphoma.
|
